I have no idea how many doctors or potential Amarin customers see an article such as the one referencing the difference in cost between Vascepa and generics, but the company should correct the errors publicly if the article is way off the mark. Everything said in the responses to my original post sound entirely reasonable as explanations for the discrepancies. You're right that Amarin doesn't manufacture anything. I remember JT saying after the Judge Du decision that Amarin had a big advantage over generics in that it had worked with multiple Vascepa suppliers for years to perfect Vascepa in the manufacturing process and that it was difficult for these factories to get it right and generics wouldn't be able to immediately find manufacturers who could crank out a lot of product.
Then Amarin began taking those dreadful $10 million hits to earnings because it couldn't sell enough Vascepa to keep up with its contracts and had to renegotiate them and presumably make these $10 million payments as a penalty. It did seem a little curious that when Vascepa stopping having these $10 million earnings hits, they began having to dramatically drop Vascepa's price. So maybe they found a way to pass along the penalty fees without having to pay millions in single quarterly payments.
But it's also possible that the article is wrong and that the price of the generic is much closer to Vascepa's price, which I recall KM saying once was about a 15 percent difference. If the article is wrong, Amarin should get them to correct it.
Market Data 
Markets 
AI
